— Know what they know.
Not Investment Advice

TRML NASDAQ

Tourmaline Bio, Inc.
1W: +0.0% 1M: +0.2% 3M: +120.5% 1Y: +74.8% 3Y: +574.8%
$47.98
Last traded 2025-10-30 — delisted
NASDAQ · Healthcare · Biotechnology · $1.2B mcap · 17M float · 5.51% daily turnover · Short 56% of daily vol

Cash Flow Trends

Operating Cash Flow
-$77M -175.1% ▼
Capital Expenditures
$9K +83.9% ▲
5Y CAGR: -56.3%
Free Cash Flow
-$77M -174.6% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$110M -183.2% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2020FY2021FY2022FY2023FY2024
— Operating Activities —
Net Income-$23M-$48M-$20M-$42M-$73M
Depreciation & Amort.$447K$623K$6K$33K$39K
Stock-Based Comp.$0$0$195K$6M$7M
Change in Working Capital$2M$2M$902K-$168K-$3M
Other Non-Cash Items$1M$5M$12M$8M-$8M
Operating Cash Flow-$19M-$40M-$6M-$28M-$77M
— Investing Activities —
Capital Expenditures-$1M-$2M-$68K-$56K-$9K
Acquisitions (Net)$0$0-$5M$0$0
Investment Purchases-$158M-$276M$0-$17M-$366M
Investment Sales$26M$182M$0$20M$172M
Other Investing-$1K$0$0$0$0
Investing Cash Flow-$133M-$96M-$5M$4M-$194M
— Financing Activities —
Net Debt Issuance$0$0-$150K$0$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$0-$277K$0-$6M-$4K
Financing Cash Flow$131M$137M$20M$157M$161M
Net Change in Cash-$21M$1M$8M$132M-$110M
Cash End of Period$18M$19M$8M$141M$31M
Free Cash Flow-$20M-$42M-$12M-$28M-$77M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms